Preclinical molecular imaging of the translocator protein (TSPO) in a metastases model based on breast cancer xenografts propagated in the murine brain

Current Molecular Medicine

Volumn 12, Issue 4, 2012, Pages 458-466

  Wyatt, Shelby K ^a,b,h   Manning, H Charles ^a,b,c,d,e   Bai, Mingfeng ^g   Ehtesham, Moneeb ^b   Mapara, Khubaib Y ^b   Thompson, Reid C ^b   Bornhop, Darryl J ^d,e,f  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VANDERBILT INGRAM CANCER CENTER   (United States)

^f VANDERBILT UNIVERSITY   (United States)

^g UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^h GENENTECH INC   (United States)

Author keywords

Breast cancer; Metastasis; Molecular imaging; Peripheral benzodiazepine receptor; PK 11195; Translocator protein

Indexed keywords

CARBON 11; DYE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; PROTEIN; TRANSLOCATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOLECULAR IMAGING; MOUSE; NEAR INFRARED SPECTROSCOPY; NONHUMAN; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

MURINAE; MUS;

EID: 84860271154     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524011207040458     Document Type: Article

References (46)

1. American Cancer Society. Cancer Facts and Figures 2012.
2. Cheng X, Hung MC. Breast cancer brain metastases. Cancer Metastasis Rev 2007; 26: 635-43.
3. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004; 22: 3608-17.
4. Palmieri D, Smith QR, Lockman PR, et al. Brain metastases of breast cancer. Breast Dis 2006; 26: 139-47.
5. Rugo HS. The importance of distant metastases in hormonesensitive breast cancer. Breast 2008; 17 Suppl 1: S3-8.
6. Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS. Breast cancer metastasis to the central nervous system. Am J Pathol 2005; 167: 913-20.
7. Sharma M, Abraham J. CNS metastasis in primary breast cancer. Expert Rev Anticancer Ther 2007; 7: 1561-6.
8. Schaller BJ, Cornelius JF, Sandu N, Buchfelder M. Molecular imaging of brain tumors personal experience and review of the literature. Curr Mol Med 2008; 8: 711-26.
9. Heyn C, Ronald JA, Mackenzie LT, MacDonald IC, Chambers AF, Rutt BK, Foster PJ. In vivo magnetic resonance imaging of single cells in mouse brain with optical validation. Magn Reson Med 2006; 55: 23-9.
10. Heyn C, Ronald JA, Ramadan SS, et al. In vivo MRI of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis to the brain. Magn Reson Med 2006; 56: 1001-10.
11. Song HT, Jordan EK, Lewis BK, Gold E, Liu W, Frank JA. Quantitative T(2)* imaging of metastatic human breast cancer to brain in the nude rat at 3 T. NMR Biomed 2011; 24: 325-34.
12. Song HT, Jordan EK, Lewis BK, et al. Rat model of metastatic breast cancer monitored by MRI at 3 tesla and bioluminescence imaging with histological correlation. J Transl Med 2009; 7: 88.
13. Bai M, Wyatt SK, Han Z, Papadopoulos V, Bornhop DJ. A novel conjugable translocator protein ligand labeled with a fluorescence dye for in vitro imaging. Bioconjug Chem 2007; 18: 1118-22.
14. Deane NG, Manning HC, Foutch AC, et al. Targeted imaging of colonic tumors in smad3-/-mice discriminates cancer and inflammation. Mol Cancer Res 2007; 5: 341-9.
15. Manning HC, Goebel T, Marx JN, Bornhop DJ. Facile, efficient conjugation of a trifunctional lanthanide chelate to a peripheral benzodiazepine receptor ligand. Org Lett 2002; 4: 1075-8.
16. Manning HC, Goebel T, Thompson RC, Price RR, Lee H, Bornhop DJ. Targeted molecular imaging agents for cellularscale bimodal imaging. Bioconjug Chem 2004; 15: 1488-95.
17. Manning HC, Smith SM, Sexton M, et al. A peripheral benzodiazepine receptor targeted agent for in vitro imaging and screening. Bioconjug Chem 2006; 17: 735-40.
18. Wyatt SK, Manning HC, Bai M, et al. Molecular imaging of the translocator protein (TSPO) in a pre-clinical model of breast cancer. Mol Imaging Biol 2010; 12: 349-58.
19. Han Z, Slack RS, Li W, Papadopoulos V. Expression of peripheral benzodiazepine receptor (PBR) in human tumors: relationship to breast, colorectal, and prostate tumor progression. J Recept Signal Transduct Res 2003; 23: 225-38.
20. Hardwick M, Fertikh D, Culty M, Li H, Vidic B, Papadopoulos V. Peripheral-type benzodiazepine receptor (PBR) in human breast cancer: correlation of breast cancer cell aggressive phenotype with PBR expression, nuclear localization, and PBR-mediated cell proliferation and nuclear transport of cholesterol. Cancer Res 1999; 59: 831-42.
21. Maaser K, Grabowski P, Sutter AP, et al. Overexpression of the peripheral benzodiazepine receptor is a relevant prognostic factor in stage III colorectal cancer. Clin Cancer Res 2002; 8: 3205-9.
22. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 2006; 11: 812-8.
23. Weissleder R. A clearer vision for in vivo imaging. Nat Biotechnol 2001; 19: 316-7.
24. Banati RB, Newcombe J, Gunn RN, et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000; 123 (Pt 11): 2321-37.
25. Venneti S, Lopresti BJ, Wiley CA. The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging. Prog Neurobiol 2006; 80: 308-22.
26. Yasuno F, Ota M, Kosaka J, et al. Increased binding of peripheral benzodiazepine receptor in Alzheimer's disease measured by positron emission tomography with [11C]DAA1106. Biol Psychiatry 2008; 64: 835-41.
27. Junck L, Olson JM, Ciliax BJ, et al. PET imaging of human gliomas with ligands for the peripheral benzodiazepine binding site. Ann Neurol 1989; 26: 752-8.
28. Owen DR, Gunn RN, Rabiner EA, et al. Mixed-affinity binding in humans with 18-kDa translocator protein ligands. J Nucl Med 2011; 52: 24-32.
29. Peters TM. Image-guidance for surgical procedures. Phys Med Biol 2006; 51: R505-40.
30. Sinha TK, Miga MI, Cash DM, Weil RJ. Intraoperative cortical surface characterization using laser range scanning: preliminary results. Neurosurgery 2006; 59: ONS368-76; discussion ONS376-67.
31. LeRoux PD, Berger MS, Ojemann GA, Wang K, Mack LA. Correlation of intraoperative ultrasound tumor volumes and margins with preoperative computerized tomography scans. An intraoperative method to enhance tumor resection. J Neurosurg 1989; 71: 691-8.
32. Sosna J, Barth MM, Kruskal JB, Kane RA. Intraoperative sonography for neurosurgery. J Ultrasound Med 2005; 24: 1671-82.
33. Gebhart SC, Majumder SK, Mahadevan-Jansen A. Comparison of spectral variation from spectroscopy to spectral imaging. Appl Opt 2007; 46: 1343-60.
34. Lin WC, Toms SA, Johnson M, Jansen ED, Mahadevan-Jansen A. In vivo brain tumor demarcation using optical spectroscopy. Photochem Photobiol 2001; 73: 396-402.
35. Lin WC, Toms SA, Motamedi M, Jansen ED, Mahadevan-Jansen A. Brain tumor demarcation using optical spectroscopy; an in vitro study. J Biomed Opt 2000; 5: 214-20.
36. Toms SA, Lin WC, Weil RJ, Johnson MD, Jansen ED, Mahadevan-Jansen A. Intraoperative optical spectroscopy identifies infiltrating glioma margins with high sensitivity. Neurosurgery 2005; 57: 382-91; discussion 382-91.
37. Haglund MM, Berger MS, Hochman DW. Enhanced optical imaging of human gliomas and tumor margins. Neurosurgery 1996; 38: 308-17.
38. Haglund MM, Hochman DW, Spence AM, Berger MS. Enhanced optical imaging of rat gliomas and tumor margins. Neurosurgery 1994; 35: 930-40; discussion 940-31.
39. Ichioka T, Miyatake S, Asai N, et al. Enhanced detection of malignant glioma xenograft by fluorescein-human serum albumin conjugate. J Neurooncol 2004; 67: 47-52.
40. Kircher MF, Mahmood U, King RS, Weissleder R, Josephson L. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res 2003; 63: 8122-5.
41. Moore GE. Fluorescein as an agent in the differentiation of normal and malignant tissues. Science 1947; 106: 130-1.
42. Popescu MA, Toms SA. In vivo optical imaging using quantum dots for the management of brain tumors. Expert Rev Mol Diagn 2006; 6: 879-90.
43. Stummer W, Novotny A, Stepp H, Goetz C, Bise K, Reulen HJ. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg 2000; 93: 1003-13.
44. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006; 7: 392-401.
45. Stummer W, Stocker S, Wagner S, et al. Intraoperative detection of malignant gliomas by 5-aminolevulinic acidinduced porphyrin fluorescence. Neurosurgery 1998; 42: 518-25; discussion 525-16.
46. Trehin R, Figueiredo JL, Pittet MJ, Weissleder R, Josephso L, Mahmood U. Fluorescent nanoparticle uptake for brain tumor visualization. Neoplasia 2006; 8: 302-11.